Spruce Biosciences is cutting over half of its employees as it looks to secure accelerated approval of a Sanfilippo syndrome therapy it recently acquired from BioMarin.
https://www.biospace.com/job-trends/spruce-axes-55-of-staff-leaving-shoestring-crew-to-focus-on-new-rare-disease-asset